You are here

Pharma Industry Seems to Be Sticking to Price-Cap Pledge

Of 30-plus price hikes, all have so far honored a 10% cap, GlobalData says

The new year has again coincided with a hike in U.S. drug prices, with more than 30 drugs seeing an increase. However, after receiving continued criticism from both the public and politicians, the industry appears to be sticking within a 10% self-imposed price-hike limit, according to consultant GlobalData.

This 10% cap appears to have become a social contract of sorts in the pharma industry since 2016, when Allergan CEO Brent Saunders pledged to police pricing. He stated that Allergan would limit itself to one price increase per year and would only increase prices by single-digit percentages.

So far, this promise has held true. None of the price hikes seen in the new year has exceeded 9.9%. Pharma companies such as Teva, Cellectis, Insys, Synergy, and Supernus have all raised their drug prices while staying within this limit. In line with its own pledge, Allergan has raised the price of 18 medications by 9.5%.

“As rising drug prices continue to be a major cause for discord in the U.S., the self-regulation of price hikes could help the industry avoid regulatory reform,” said Alice Stevens, Healthcare Analyst at GlobalData. “With rising drug prices more constrained in 2017 and 2018, the pharma industry may be on its way to dodging federal regulation.”

However, this more conservative approach to price increases is merely a commitment between drug makers, and relies solely on the industry adhering to a pledge. As this is not an obligation, not every company is likely to follow suit. For example, during 2017, Pfizer and Celgene raised the prices of drugs by 19.8% and 27.5%, respectively.

 “It remains unclear how long this social contract will last,” Stevens said. “Although many companies seem to be willing to adhere to Allergan’s pledge at present, the need for higher revenues may see another rise in drug prices before the year is out.”

Source: GlobalData; February 12, 2018.

More Headlines

Nearly 68% of patients treated with AR101 could tolerate peanut protein
Tablets are also indicated to treat drug-induced extrapyramidal reactions
But lawmakers are far from united on the issue
New CEO believes “breakthrough innovations” are key to future growth
Law journal article considers the strategy’s legal and ethical implications
First treatment for patients with inoperable tumors after chemoradiation
Benefits reported in treating plaque psoriasis, oral ulcers, and genital psoriasis
Award was largest ever in a U.S. patent case
So far, 20,000 people have been hospitalized